Saturated fats, dairy foods and health: a curious paradox?


It is advisable to refer to the publisher's version if you intend to cite from the work. See Guidance on citing.

To link to this article DOI: http://dx.doi.org/10.1111/nbu.12283

Publisher: Wiley-Blackwell

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the End User Agreement.

www.reading.ac.uk/centaur

CentAUR
Central Archive at the University of Reading
Cardiovascular diseases (CVD) remain a major cause of death and morbidity worldwide. Dietary guidelines aim to restrict the intake of saturated fatty acids (SFA) as they are regarded as an important risk factor for CVD due to their association with increased blood cholesterol. As dairy foods are major contributors of dietary SFA, there have been guidelines to reduce consumption of these foods. However, it is now generally accepted that the effects of reducing intake of SFA are dependent on what replaces them in the diet. Reduced CVD risk has been associated with replacement of SFA with cis-polyunsaturated fatty acids (cis-PUFA) and/or cis-monounsaturated fatty acids (cis-MUFA), with replacement by carbohydrate leading to no reduction or even increased CVD risk. Most studies on the effect of diet/food on CVD risk have used total cholesterol (TC) and/or low-density lipoprotein cholesterol (LDL-C) in blood as the marker(s) of risk. However, because of potentially attenuating effects of dairy foods (e.g. effect of protein on blood lipids and blood pressure; food matrix effects on fat bioavailability), a wider range of markers is needed to more fully evaluate disease risk. Nevertheless, whilst prospective evidence shows no increase in CVD risk from high dairy consumption, it is still unclear whether replacing a proportion of SFA in dairy fat with cis-MUFA will lead to reduced CVD risk. The relatively few randomised controlled trials that have examined this using TC/LDL-C as risk markers give some indications of reduced CVD risk from consumption of milk and dairy products with modified fatty acid composition, compared with those of normal milk fat composition. The results of ongoing studies will add valuable new evidence on this issue.

**Keywords:** cardiovascular disease, dairy products, fatty acids, milk

**Introduction**

Despite improved prevention and treatment programmes, cardiovascular disease (CVD) remains a major cause of death and morbidity in the European Union (EU) (Wilkins et al. 2017) and worldwide (Forouzanfar et al. 2015). Although CVD mortality is now decreasing in most European countries, there are some 49 million people living with CVD in the EU with an estimated cost of €210 billion/year (Wilkins et al. 2017). Moreover, the increase in prevalence of overweight/obesity and type 2 diabetes seen in the EU in recent times casts doubt on whether the current reduction in CVD mortality is sustainable. It is therefore imperative that modifiable risk factors for CVD, such as diet, are used to their full advantage.
A high intake of saturated fatty acids (SFA) has for many years been regarded as an important risk factor for CVD, leading to public health targets recommending a dietary SFA intake that should not be exceeded. In the UK, this recommendation, currently being reviewed, is that SFA intake should not exceed 11% of food energy intake but, as shown in Table 1, intake for all age groups in the National Diet and Nutrition Survey (Bates et al. 2014) exceeds this target. Table 1 also shows that milk and dairy products (including butter) are major sources of dietary SFA and this has led to some proposals to reduce dairy product consumption in order to reduce SFA intake. Recent evidence suggests that this approach is likely to be too simplistic (Thorning et al. 2017).

### Effects of saturated fat consumption

Recent meta-analyses of prospective studies (Siri-Tarino et al. 2010; Chowdhury et al. 2014; de Souza et al. 2015) have raised doubts about whether a high intake of SFA is a risk factor for CVD. The specific effect of SFA on CVD risk is well established and is mainly mediated via increases in blood lipids, particularly low-density lipoprotein cholesterol (LDL-C) (Griffin 2017). There is strong evidence implicating LDL-C as a risk factor in CVD events (Ridker 2014) and randomised controlled trials (RCT) with LDL-C lowering interventions have confirmed a causal relationship between blood LDL-C and CVD, particularly coronary heart disease (CHD; Marz et al. 2016). However, as highlighted by Mensink et al. (2003), SFA can also increase high-density lipoprotein cholesterol (HDL-C), generally regarded as being associated with reduced CVD risk. It should also be noted that blood LDL-C contains the cholesterol present in all LDL particles, with the small, dense LDL particles (sdLDL), whilst containing less cholesterol per particle than other LDL particles, are more strongly associated with increased CHD risk than the larger less dense LDL particles (Hoogeveen et al. 2014). One cross-sectional study in healthy Swedish men indicated that dietary fatty acids typically found in dairy foods gave rise to significantly less sdLDL particles (Sjögren et al. 2004). In particular, SFA 4:0 to 10:0 and 14:0 (P < 0.05) in the diet and 15:0 and 17:0 (markers of dairy fat intake) in serum phospholipids (P < 0.05) were associated with fewer sdLDL particles. This study suggests that LDL particle size distribution may be favourably modified by dairy products in the diet but this needs further investigation.

### Substitution of dietary saturated fatty acids with unsaturated fatty acids

As noted above, data from prospective studies (Siri-Tarino et al. 2010; de Souza et al. 2015) have cast doubts on the traditional view of SFA as a risk factor for CVD. Recently, an expert group met to review this conflict (Nettleton et al. 2017). Their key recommendation was that it is vitally important to understand the effect of replacing SFA in the diet. Nettleton et al. (2017) concluded that the greatest reduction in CHD risk was seen when dietary SFA are replaced with cis-polyunsaturated fatty acids (cis-PUFA) although there was little effect on risk of stroke. They cited RCTs which showed that replacement of 10% and 5% of energy from SFA by cis-PUFA reduced CVD events by 27% and 10%, respectively. It is also noteworthy that replacement of SFA with refined carbohydrate is associated with no improvement or even an increase in CVD risk (Micha & Mozaffarian 2010).

Nettleton et al. (2017) also reported that there are insufficient data to draw conclusions on the effect of replacing SFA with cis-MUFA, although there are a number of important studies. A cross-sectional population study by Miura et al. (2013) reported a linear inverse association between cis-MUFA (especially oleic acid) intake and diastolic blood pressure, and in the recruited population study of Hassan et al. (2015), dietary oleic acid intake was negatively associated with systolic and diastolic blood pressure. Recently, the RCT of Liu et al. (2016) compared diets high in cis-PUFA with those high in cis-MUFA and showed that the latter reduced abdominal obesity with accompanying reductions in blood pressure and blood

---

### Table 1 Mean daily intake of saturated fatty acids (SFA) and as a percentage of food energy (FE) and total energy (TE) by gender and age, together with the contribution of dairy foods to SFA intake in the UK (from Bates et al. 2014)

<table>
<thead>
<tr>
<th></th>
<th>Males (years of age)</th>
<th>Females (years of age)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>4–10</td>
<td>11–18</td>
</tr>
<tr>
<td>SFA (g/day)</td>
<td>23.0</td>
<td>27.8</td>
</tr>
<tr>
<td>SFA % FE</td>
<td>13.1</td>
<td>12.7</td>
</tr>
<tr>
<td>SFA % TE</td>
<td>13.1</td>
<td>12.6</td>
</tr>
<tr>
<td>Contribution</td>
<td>34</td>
<td>26</td>
</tr>
<tr>
<td>of dairy foods</td>
<td>to total SFA intake (%)</td>
<td></td>
</tr>
</tbody>
</table>
triacylglycerols (TAG). The Reading, Imperial, Surrey, Cambridge, and Kings (RISCK) study (Jebb et al. 2010) showed that replacing SFA with cis-MUFA, compared to replacement with carbohydrate, reduced the total cholesterol (TC):HDL-C ratio and, more recently, the Dietary Intervention and VAScular function (DIVAS) study (Vafeiadou et al. 2015) showed that replacement of about 9.6% of energy from SFA by MUFA lowered serum TC by 8.4%, LDL-C by 5.6% (P <0.001). Thus, overall, there is mounting evidence that replacing dietary SFA with cis-MUFA may be beneficial for reducing the risk of CVD and associated factors in the metabolic syndrome.

Dairy consumption and cardiometabolic disease

Evidence from prospective cohort studies

Numerous studies have investigated the association between milk and dairy product consumption and cardiometabolic diseases (CMD; CVD + type 2 diabetes). Whilst prospective study data are regarded as providing weaker evidence than RCT data on the diet/food–disease relationship, they have the advantage of looking at long-term effects and use real disease events as the outcome measures. Very long-term RCTs using disease data would be impractical and very expensive, and this means that most RCTs use markers of disease risk (e.g. LDL-C) as primary outcome measures. Meta-analysis of prospective studies is a valuable tool for looking at the overall association between dairy foods and CMD risk, although there remains a concern that in many studies the dairy foods involved are poorly defined which limits assessment of the relative effects of different dairy foods. This is particularly the case when comparing high-fat vs. low-fat dairy products. Early meta-analyses of prospective cohort studies reported that, overall, high milk consumption does not increase the relative risk (RR) of CHD (Elwood et al. 2008, 2010). A further meta-analysis, which combined prospective cohort and clinical studies, also indicated no significant increase in the RR of CHD in high vs. low milk consumers (RR 0.94; 95% CI, 0.75–1.13) (Mente et al. 2009).

A number of dose–response meta-analyses have been published recently examining the association between dairy food consumption and type 2 diabetes (Gijsbers et al. 2016), stroke (de Goede et al. 2016), and CVD and all-cause mortality (Guo et al. 2017). These are the most up-to-date dose–response meta-analyses available and the results are summarised in Table 2. Overall, these studies show no increase in risk of CVD per unit increase in milk and cheese consumptions and a significant reduction in risk of stroke per unit consumption of cheese and milk. Interestingly, yoghurt consumption was associated with a reduced risk of type 2 diabetes (Gijsbers et al. 2016). There are few studies examining the effects of butter on CMD but the recent dose–response meta-analysis of Pimpin et al. (2016) indicates no significant association between butter consumption and all-cause mortality, CVD, CHD or stroke, although there was a significant negative association with type 2 diabetes (Table 2). The meta-analysis of Pimpin et al. (2016) involved relatively few cohorts for CVD (n = 4), CHD (n = 3), stroke (n = 3) although 11 cohorts were suitable for inclusion for type 2 diabetes.

Evidence from randomised controlled trials

Given the evidence linking SFA intake with blood levels of LDL-C, and blood levels of LDL-C with CVD risk, and the fact that dairy foods are major contributors to SFA, the consistent neutral or beneficial associations between dairy foods and CVD from analysis of prospective data remain something of a paradox to many. There is, however, increasing evidence

<table>
<thead>
<tr>
<th>Dairy food</th>
<th>Outcome</th>
<th>RR (95% CI)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Milk (per 244 g/day)</td>
<td>All-cause mortality</td>
<td>1.00 (0.93–1.07)</td>
<td>Guo et al. (2017)</td>
</tr>
<tr>
<td>Milk (per 244 g/day)</td>
<td>CVD</td>
<td>1.01 (0.93–1.10)</td>
<td>Guo et al. (2017)</td>
</tr>
<tr>
<td>Cheese (per 10 g/day)</td>
<td>CVD</td>
<td>0.98 (0.95–1.00)</td>
<td>Guo et al. (2017)</td>
</tr>
<tr>
<td>Yoghurt (per 50 g/day)</td>
<td>CVD</td>
<td>1.03 (0.97–1.09)</td>
<td>Guo et al. (2017)</td>
</tr>
<tr>
<td>Milk (per 200 g/day)</td>
<td>Stroke</td>
<td>0.93 (0.88–0.98)</td>
<td>de Goede et al. (2016)</td>
</tr>
<tr>
<td>Cheese (per 40 g/day)</td>
<td>Stroke</td>
<td>0.97 (0.94–1.01)</td>
<td>de Goede et al. (2016)</td>
</tr>
<tr>
<td>Yoghurt (per 80 g/day)</td>
<td>Type 2 diabetes</td>
<td>0.86 (0.83–0.90)</td>
<td>de Goede et al. (2016)</td>
</tr>
<tr>
<td>Butter (per 14 g/day)</td>
<td>All-cause mortality</td>
<td>1.01 (1.00–1.03)</td>
<td>Gijsbers et al. (2016)</td>
</tr>
<tr>
<td>Butter (per 14 g/day)</td>
<td>CVD</td>
<td>1.00 (0.98–1.02)</td>
<td>Pimpin et al. (2016)</td>
</tr>
<tr>
<td>Butter (per 14 g/day)</td>
<td>CHD</td>
<td>0.99 (0.96–1.03)</td>
<td>Pimpin et al. (2016)</td>
</tr>
<tr>
<td>Butter (per 14 g/day)</td>
<td>Stroke</td>
<td>1.01 (0.93–0.99)</td>
<td>Pimpin et al. (2016)</td>
</tr>
<tr>
<td>Butter (per 14 g/day)</td>
<td>Type 2 diabetes</td>
<td>0.96 (0.93–0.99)</td>
<td>Pimpin et al. (2016)</td>
</tr>
</tbody>
</table>

CI, confidence interval; CVD, cardiovascular disease; CHD, coronary heart disease.
that goes some way to explain why meta-analyses of prospective studies show no increased risk of CVD in high dairy consumers.

In the UK, up to 30% of adults are hypertensive (Townsend et al. 2015) and hypertension is one of the major risk factors for CVD development and stroke, in particular. Gene polymorphisms, nutrition, the environment and interactions between these factors contribute to the development of hypertension. Milk and milk-derived products provide essential micronutrients (e.g. calcium, magnesium, iodine and vitamin D) and proteins (whey, casein and specific bioactive peptides) some of which have been associated with beneficial hypotensive effects, either independently or in combination within dairy foods (Kris-Etherton et al. 2009).

A recent 8-week RCT (Fekete et al. 2016) showed that whey protein isolate (two doses of 28 g, mixed with water, per day) had a greater hypotensive effect than casein and the effects were seen on both central and peripheral blood pressures. A number of mechanisms by which milk and its components could lower blood pressure (BP) have been proposed (Fekete et al. 2013). Peptides released during digestion of casein and whey proteins have been shown to have hypotensive effects by inhibiting the action of angiotensin-I-converting enzyme, resulting in vasodilation (FitzGerald & Meisel 2000) by modulating the release of endothelin-1 by endothelial cells (Maes et al. 2004) and acting as opioid receptor ligands increasing nitric oxide production, which mediates arterial tone (Kris-Etherton et al. 2009). There is little firm evidence for differential effects of low- vs. high-fat dairy foods on hypertension. For example, whilst Engberink et al. (2009) reported an inverse association between low-fat dairy intake and risk of hypertension in older adults, others have shown that both low- and high-fat milk products have hypotensive effects (Ralston et al. 2012). In addition, results from the Caerphilly Prospective Study showed that when compared with non-milk consumers, men who consumed >586 ml/day of milk had on average a 10.4 mmHg lower systolic BP after a 22.8-year follow-up (Livingstone et al. 2013). Some of the inconsistencies between studies may well relate to the lack of a consistent definition of what constitutes low- and high-fat dairy foods.

There is now good evidence that arterial stiffness, especially of the large vessels, is an important predictor of CVD events (Cockcroft & Wilkinson 2000) and this can be affected by dietary patterns (Kesse-Guyot et al. 2010). The measurement of carotid-femoral pulse wave velocity (PWV) is regarded as the gold standard for assessing arterial stiffness and can independently predict CVD events (Sutton-Tyrrell et al. 2005; Van Bortel et al. 2012). Livingstone et al. (2013), using data from the Caerphilly Prospective Study, showed for the first time in a longitudinal study that dairy product consumption (not including butter) does not increase PWV (i.e. no indication of increased arterial stiffness). Moreover, the measurement of augmentation index, another indicator of arterial stiffness, was 1.9% units lower ($P = 0.021$) in men with the highest dairy consumption (Livingstone et al. 2013). A cross-sectional study also reported that consumption of dairy foods was negatively associated with PWV (Crichton et al. 2012).

**Food matrix effects of dairy products on blood lipids**

Traditional nutritional evaluation of foods and diets and their relationship with the health of the consumer has generally been based on separate assessments of individual food components such as protein, fat, carbohydrates and micronutrients. This approach of associating one nutrient to one health effect (e.g. SFA intake to CVD risk) may explain some of the discrepancies between a food’s predicted health effect, based on its nutrient content, and its actual health effect when consumed as a whole food. There is increasing evidence that for an accurate evaluation of the health effects of some dairy foods, the so-called food matrix does indeed need to be taken into account. This topic has recently been extensively reviewed by a Working Party set up by the Universities of Copenhagen and Reading, and the conclusions are reported by Thorn- ing et al. (2017). The Working Party concluded that ‘Evidence to date indicates the dairy matrix has specific beneficial effects on health, as the metabolic impact of whole dairy on bodyweight, cardiometabolic disease risk, and bone health differ to that of single dairy constituents. Also, different types of dairy products seem to be distinctly linked to various health effects and disease risk markers. In addition, different processing methods and dairy structures can enhance interactions in the dairy matrix, thereby modifying the metabolic effects of dairy consumption. The nutritional value of dairy products should therefore be considered as the biofunctionality of the sum of nutrients within the dairy matrix structures’.

A good example of the differential effects on blood lipids of SFA intake from cheese and butter is shown in the RCT of Hjerpsted et al. (2011), which consisted of two 6-week crossover periods with 49 men and women replacing part of their habitual dietary fat with 13% of energy from cheese or butter (80 g/day
and 36 g/day of total fat and SFA, respectively). The cheese and butter diets provided 1192 g and 417 g of calcium/day, respectively. Relative to baseline, cheese did not increase TC or LDL-C whereas butter increased both (P < 0.001 and < 0.05, respectively), and additionally cheese intake led to a 5.7% and 6.9% lower TC and LDL-C concentrations, respectively (P < 0.0001), compared with butter. Various mechanisms have been suggested as being responsible for the health benefits of this so-called matrix effect, and the study of Lorenzen and Astrup (2011) identified mechanisms which could contribute to the differential effects of cheese and butter on blood cholesterol. They randomised study participants to one of four isoenergetic diets comprising low-fat (25% energy intake) and high-fat diets (40% energy intake), each of which contained either low (700 mg/day) or high (2800 mg/day) calcium. The key results are summarised in Table 3. Increasing calcium intake increased faecal fat and bile acid excretion in both low- and high-fat diets, although the high-fat diets also increased faecal fat loss. Lorenzen and Astrup (2011) proposed that the key effect of calcium on faecal fat and bile acid excretion is likely to be the result of formation of insoluble calcium-fatty acid soaps and/or of hydrophobic aggregations with phosphorus and bile acids. Increased faecal fat excretion is indicative of reduced fat absorption and hence a moderated blood cholesterol response, whilst increased bile acid excretion would reduce the amount that was recycled via the enterohepatic circulation. Reduced bile acid recycling would lead to increased metabolism of cholesterol for bile acid synthesis, thus reducing that in the circulation.

These studies indicate that the impact of dairy foods on CVD risk factors may be dependent on the food matrix, even for dairy foods that supply the same amount of dairy fat and SFA. However, as concluded by Thorning et al. (2017), further work is needed to fully understand food matrix effects on health and how these relate to specific dairy foods and methods of processing.

Effects of milk proteins on blood lipids

Whilst most studies have reported on the effect of dairy fat/fatty acids on blood lipids, there is now evidence that milk proteins can also influence blood lipids. The study of Tong et al. (2014), using a high-fat diet with rats, found that whey protein significantly increased HDL-C, although studies with humans have not always shown the same effect (Chiu et al. 2014). Some studies have shown that whey protein tends to reduce plasma TAG (Pal et al. 2010) and TC (Petyaev et al. 2012). The study of Mariotti et al. (2015) showed that compared with whey protein, casein markedly reduced postprandial TAG (22 ± 10% reduction in the 6-hour area under the curve, P < 0.05). Similar effects were seen for plasma chylomicrons (apoB-48; P < 0.05). The recent study of Fekete et al. (2016) reported that whilst whey protein and calcium caseinate both significantly reduced TC (–20.26 mmol/l, P = 0.013 and –20.20 mmol/l, P = 0.042, respectively), only whey protein reduced TAG (–20.23 mmol/l, P = 0.025) compared with the control.

Overall, these studies indicate that milk proteins can have important lowering effects on blood lipids, which may moderate any opposite effects of dairy fats and be a contributing factor to the neutral or health benefits of dairy foods observed in prospective studies. Nevertheless, it is clear that more work in this area is needed and supports the proposal of Lovegrove and Givens (2016) for a meta-analysis of effects of milk proteins on blood lipids.

Replacing saturated fatty acids in milk fat by modifying the diet of the dairy cow

Milk fat per 100 g typically contains 70–75 g SFA, 20–25 g cis-MUFA and small (2–5 g) amounts of cis-PUFA (Kliem et al. 2013a). Fatty acids in milk fat originate from two sources, either by direct incorporation from the peripheral circulation or from de novo synthesis in the mammary gland using short-chain (2:0 and 4:0) precursors. Mammary de novo synthesis accounts for all 4:0 to 12:0 fatty acids, most of the 14:0 and typically about half of 16:0 secreted in milk, while all 18:0 and longer-chain fatty acids are derived entirely from circulating plasma lipids (Hawke & Taylor 1995). Modification of the fatty acid profile of milk offers a strategy for lowering the population’s

![Table 3](image-url)
intake of SFA, by reducing SFA in the food chain, whilst preserving the beneficial contributions that dairy products make to the protein and micronutrient content of the human diet (Kliem & Givens 2011). Over 100 studies have explored the potential of partially replacing milk SFA with cis-MUFA or cis-PUFA through supplementation of the dairy cow diet with plant oils or oilseeds (Glasser et al. 2008). Broadly, the target is to increase the supply of long-chain fatty acids (of chain length 18 carbons and above) to the mammary gland, which inhibit the synthesis of short- and medium-chain SFA (Givens & Shingfield 2006). The inclusion of oilseeds in cows’ diets typically produces reductions in the SFA content of 100 g of milk fat from 70 g to between 55 and 60 g (Givens & Shingfield 2006). One study in the EU-funded LIPGENE project (involving BNF and the University of Reading) examined the effect of form of rapeseed lipid in the diet of the dairy cow on the reduction in milk SFA and increase in cis-MUFA that could be achieved (Givens et al. 2009). The cows’ diet treatments were no rapeseed lipid (control) or rapeseed lipid in the form of rapeseed oil, whole, unprocessed rapeseeds or milled rapeseeds. The inclusion of 49 g of rapeseed oil per kg of dry matter in the diet for a 28-day period increased cis-MUFA from 23 to 29 g per 100 g of milk fat, while reducing SFA from 70 to 56 g per 100 g of milk fat. It is clear that using whole, unprocessed rapeseed is not a viable option but the other two rapeseed lipid forms reduced SFA (notably 16:0) and increased cis-MUFA (notably cis-18:1). As part of the Biotechnology and Biological Sciences Research Council Diet and Health Research Industry Club (BBSRC DRINC) funded series of studies, Kliem et al. (2013b) showed that increasing amounts of an experimental calcium salt of cis-MUFA in the cows’ diet produced a linear reduction in SFA and a linear increase in cis-MUFA in the milk fat. A summary of these results is shown in Table 4. The recent study of Markey et al. (2015a) showed similar changes in the composition of milk fat as a result of using high oleic sunflower oil in the diet of the cow.

As seen in Table 4, the inclusion of unsaturated fatty acids in the dairy cow diet can lead to increased concentrations of naturally produced ruminant trans-fatty acids (rTFA), predominantly trans-MUFA, in the milk. The intake of trans-fatty acids (TFA) from industrially hydrogenated vegetable oils is known to substantially increase the risk of CVD (de Souza et al. 2015) and, as a result, there has been a substantial reduction in the amount of industrial TFA (iTFA) in the UK food chain (SACN 2007). The association between iTFA and CVD risk has lacked good experimental evidence although negative associations between plasma trans-palmitoleic acid (trans-16:1n-7) concentration (assumed to be mainly of dairy origin) and type 2 diabetes have been reported (Mozaffarian et al. 2010, 2013). The recent meta-analysis by de Souza et al. (2015) reported that intake of iTFA, but not rTFA, was positively associated with CHD mortality and risk of CHD, and intake of rTFA inversely associated with risk of type 2 diabetes. Clearly, there is a need for more RCT-based evidence on the impact of rTFA in particular.

### Does replacing saturated fatty acids in dairy products provide health benefits?

Based on the long-standing association between SFA intake and plasma cholesterol, it would seem that changing the fatty acid composition of dairy foods to replace some SFA with cis-PUFA and/or cis-MUFA could provide a useful way to reduce SFA intake whilst retaining the nutritional and cardiometabolic

---

**Table 4 Effect of calcium salts of cis-monounsaturated fatty acids (MUFA) supplementation on key milk fatty acid families (g/100 g total fatty acids; from Kliem et al. 2013b)**

<table>
<thead>
<tr>
<th>Fatty acids</th>
<th>Treatments*</th>
<th>SEM</th>
<th>P† for</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
<td>CS2</td>
<td>CS4</td>
</tr>
<tr>
<td>Σ SFA</td>
<td>71.0</td>
<td>63.1</td>
<td>55.1</td>
</tr>
<tr>
<td>Σ cis-MUFA</td>
<td>19.9</td>
<td>24.4</td>
<td>30.8</td>
</tr>
<tr>
<td>Σ trans total</td>
<td>6.1</td>
<td>9.6</td>
<td>15.6</td>
</tr>
<tr>
<td>Σ trans-MUFA</td>
<td>4.3</td>
<td>6.2</td>
<td>10.5</td>
</tr>
<tr>
<td>Σ n-6 PUFA</td>
<td>3.1</td>
<td>3.0</td>
<td>3.2</td>
</tr>
<tr>
<td>Σ n-3 PUFA</td>
<td>0.40</td>
<td>0.41</td>
<td>0.42</td>
</tr>
</tbody>
</table>

*Where CS2, CS4 and CS6 are diets containing 20, 40 and 60 g/kg diet dry matter calcium salt, respectively; SEM, standard error of the mean.

†Significance of overall effect of diet and/or linear/quadratic responses.
benefits of milk. Indeed, using published models of cholesterol responses to SFA intake, it was predicted that, in the EU, reductions of some 10 500 and 3900 deaths from CHD and stroke per annum, respectively, could result from such a strategy (Givens 2008), although it is now clear that such a simple model is not likely to apply to all dairy foods for some of the reasons discussed above.

Livingstone et al. (2012) reviewed the RCT-based evidence on the effect on CVD risk markers of consuming dairy products modified by changing the nutrition of the dairy cow. Of the nine RCT studies identified, most used modified butter as the main test food and change in blood cholesterol was used as the primary risk marker. Of the six comparable studies that measured blood cholesterol, five and four reported significant reductions in TC and LDL-C, respectively, one showed a rise in TC and two showed no effect on LDL-C following chronic consumption of modified milk and dairy products. One study (Seidel et al. 2005) was of particular interest as it was the only study to compare the effects of modified dairy products in normocholesterolaemic (NC) and hypercholesterolaemic (HC) subjects. Dairy cows were fed a diet containing cis-MUFA-rich rapeseed cake to achieve the changes in milk fatty acid concentrations and the milk was used to produce butter and yogurt. In a 13-week, three-phase, randomised, crossover, controlled study, subjects were fed modified milk, butter and yogurt, as well as non-modified milk, margarine and yogurt. The results showed that, overall, LDL-C was reduced (−0.38 mmol/l; P <0.05) and HDL-C was increased (+0.33 mmol/l; P <0.05) when the modified products were consumed, resulting in a reduced LDL:HDL ratio (−0.43 mmol/l; P <0.05). These changes were seen in both the HC and NC subjects, interestingly, with greater change in the NC subjects. Seidel et al. (2005) proposed that this may be due to lipid metabolism in HC subjects being more complex and/or dietary intervention being less effective.

As discussed earlier, it is now clear that the use of a single marker (e.g. blood cholesterol) for predicting the cardiometabolic risk/benefit associated with consumption of fatty acid-modified dairy foods may not be adequate and that a wider range and more holistic markers are needed. A study of this type is presently underway at the University of Reading in the REPlace-ment of SaturatEd fat in dairy on Total cholesterol (RESET) study (ClinicalTrials.gov NCT02089035) – a 3.5-year project funded by the UK Medical Research Council. It is investigating the impact of reducing SFA in milk and dairy products on vascular function and a wide range of CMD risk biomarkers, after both acute and chronic consumption. Some early findings on the fatty acid composition of the dairy foods used were presented by Markey et al. (2015a) and on consumer acceptance of the SFA reduced milk, cheese and butter by Markey et al. (2015b). The blinded consumer test indicated that most consumers preferred the conventional products. This suggests that further development of modified dairy foods is needed to ensure they are acceptable to consumers. This would need to be accompanied by clear health-related information to allow consumers to make informed decisions on purchase and consumption.

Conclusions

It is now clear that the effects of reducing dietary SFA are best interpreted by an understanding of which macronutrients replace them, with reduced CVD risk being associated with the replacement of SFA with cis-PUFA and cis-MUFA. Most judgements have, however, been made using TC/LDL-C as the primary markers of CVD risk, and because of potentially counterbalancing effects in dairy food (e.g. effect of protein on blood lipids and blood pressure; matrix effects on fat bioavailability), a wider range of markers are needed. Nevertheless, whilst prospective evidence shows no increase in CVD risk from high dairy consumption, it is still unclear whether replacing a proportion of SFA in dairy fat with cis-MUFA will lead to reduced CVD risk. The relatively few RCTs that have examined this, using TC/LDL-C as the risk marker, provide some indication of reduced CVD risk from consumption of milk and dairy products with modified fatty acid composition, compared with those of normal milk fat composition. The results of ongoing studies will add valuable new evidence on this issue.

Conflict of interest

The author has no conflict of interest to disclose.

References


